Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

Abstract: The present invention is related to a composition comprising a phosphodiesterase inhibitor, such as anagrelide or a salt thereof, for use in the treatment of a solid tumor, such as gastrointestinal stromal tumor (GIST) or a liposarcoma, which express phosphodiesterase 3 enzymes, in a human patient.

Abstract: The present invention is related to a composition comprising a phosphodiesterase inhibitor, such as anagrelide or a salt thereof, for use in the treatment of a solid tumor, such as gastrointestinal stromal tumor (GIST) or a liposarcoma, which express phosphodiesterase 3 enzymes, in a human patient.

Abstract: A method for monitoring degradation a physiological sensor connected to a patient monitor is disclosed. A patient monitor, a patient monitor system, a physiological sensor, and a computer program product are also disclosed. In order to get an early warning of an imminent breakage or wear out of a physiological sensor and to increase the life time of the sensor without compromising patient safety, history data is collected for at least one sensor feature parameter into a predetermined memory location, wherein the collected history data is indicative of past characteristics of the sensor. The history data is retrieved from the predetermined memory location when the physiological sensor is connected to a patient monitor and a degradation measure indicative of the degree of degradation of the physiological sensor is determined for the physiological sensor based on the history data.

Abstract: In order to increase sensor manufacturing yield without compromising patient safety, at least one first value is determined respectively for at least one sensor feature parameter indicative of characteristics of a physiological sensor and the determined value(s) is/are stored in a predefined memory location prior to use of a physiological sensor. In response to the physiological sensor being connected to a patient monitor, at least one second value is defined respectively for the at least one sensor feature parameter and the at least one first value of each of the at least one sensor feature parameter is retrieved from the predefined memory location. Each of the at least one second value is compared with respective at least one first value and a decision is made, based on the comparison, on the acceptance of the physiological sensor.

Abstract: A method for monitoring degradation a physiological sensor connected to a patient monitor is disclosed. A patient monitor, a patient monitor system, a physiological sensor, and a computer program product are also disclosed. In order to get an early warning of an imminent breakage or wear out of a physiological sensor and to increase the life time of the sensor without compromising patient safety, history data is collected for at least one sensor feature parameter into a predetermined memory location, wherein the collected history data is indicative of past characteristics of the sensor. The history data is retrieved from the predetermined memory location when the physiological sensor is connected to a patient monitor and a degradation measure indicative of the degree of degradation of the physiological sensor is determined for the physiological sensor based on the history data.

Abstract: In order to increase sensor manufacturing yield without compromising patient safety, at least one first value is determined respectively for at least one sensor feature parameter indicative of characteristics of a physiological sensor and the determined value(s) is/are stored in a predefined memory location prior to use of a physiological sensor. In response to the physiological sensor being connected to a patient monitor, at least one second value is defined respectively for the at least one sensor feature parameter and the at least one first value of each of the at least one sensor feature parameter is retrieved from the predefined memory location. Each of the at least one second value is compared with respective at least one first value and a decision is made, based on the comparison, on the acceptance of the physiological sensor.

Abstract: A method and arrangement for detecting rotational movement. The method comprises the steps of arranging a sensor at the end of a rotation axle of a rotating object and at a distance from the rotation axle, arranging a detector external to the end of the rotation axle of the rotating object in such a manner that the distance between the sensor and detector changes as the object turns around its rotation axle, transmitting an poll to from the detector to the sensor, receiving the poll at the sensor, and in response to receiving the poll, transmitting a reply from the sensor to the detector, determining the power used in signaling, and detecting rotational movement on the basis of the change in signaling power.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N—[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).

Abstract: A method and arrangement for detecting rotational movement. The method comprises the steps of arranging a sensor at the end of a rotation axle of a rotating object and at a distance from the rotation axle, arranging a detector external to the end of the rotation axle of the rotating object in such a manner that the distance between the sensor and detector changes as the object turns around its rotation axle, transmitting an poll to from the detector to the sensor, receiving the poll at the sensor, and in response to receiving the poll, transmitting a reply from the sensor to the detector, determining the power used in signaling, and detecting rotational movement on the basis of the change in signaling power.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.